Director of Clinical Informatics, Subha Madhavan, PhD and her team are working with researchers to coordinate data from three pilot studies to test the G-DOC® program:

  • A translational breast cancer program combining two large data sets
  • A colorectal cancer study involving roughly 100 tissue samples

These pilot studies leverage the Medical Center's multi-layered expertise in breast and gastrointestinal cancer research.

  • Georgetown Lombardi's Nina Hyde Center for Breast Cancer Research, led by Claudine Isaacs, MD and Robert Clarke, PhD, DSc, is one of the world's largest and most respected centers of its kind, with nearly 50 scientists and physicians devoted to finding potential cures for the disease. Building on the momentum of G-DOC®, researchers are making strides to uncover the biological bases of the many forms of the disease, working towards its prevention and cure by delving into the multifaceted risk factors.
  • Georgetown Lombardi's new scientific director, V. Craig Jordan, OBE, PhD, DSc, brings a long list of achievements, including having revolutionized breast cancer prevention and therapy through his development of the estrogen-blocking drug tamoxifen.
  • Georgetown Lombardi's researchers and clinicians are generating novel genetic information about gastrointestinal cancers - the most common and fatal cancer category - with an emphasis on colorectal and pancreatic cancers. As a specialist in gastrointestinal oncology, Lombardi Director Louis M. Weiner, MD has introduced the use of functional genomics at Lombardi to identify the specific genes responsible for resistance to several major colorectal drugs. Lombardi's Gastrointestinal Cancers Program is led by John Marshall, MD, one of the world's leading gastrointestinal cancer-focused medical oncologists.